Compare XLO & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XLO | COHN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 40.3M |
| IPO Year | 2021 | N/A |
| Metric | XLO | COHN |
|---|---|---|
| Price | $0.64 | $20.24 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 333.3K | 79.5K |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 4.60% |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.50 |
| Revenue | $31,804,000.00 | ★ $185,475,000.00 |
| Revenue This Year | $626.78 | N/A |
| Revenue Next Year | $79.08 | N/A |
| P/E Ratio | ★ N/A | $8.72 |
| Revenue Growth | ★ 588.40 | 107.11 |
| 52 Week Low | $0.59 | $6.10 |
| 52 Week High | $1.70 | $32.60 |
| Indicator | XLO | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 50.86 |
| Support Level | $0.63 | $19.50 |
| Resistance Level | $0.63 | $23.15 |
| Average True Range (ATR) | 0.04 | 2.86 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 32.53 | 19.70 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.